Pre-made Brolucizumab benchmark antibody ( scFv, anti-VEGFA therapeutic antibody, Anti-VPF/VEGF/MVCD1 Antibody) for drug discovery and mechanism of action (MOA) research

Cat:GMP-Bios-ab-083

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

SKU GMP-Bios-ab-083 Category Tag

Product Details

Pre-Made Brolucizumab biosimilar, scFv, Anti-VEGFA Antibody: Anti-VPF/VEGF/MVCD1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Brolucizumab, sold under the trade name Beovu, is a humanized single-chain antibody fragment for the treatment of neovascular (wet) age-related macular degeneration (AMD).

Products Name (INN Index)

Pre-Made Brolucizumab biosimilar, scFv, Anti-VEGFA Antibody: Anti-VPF/VEGF/MVCD1 therapeutic antibody

INN Name

Brolucizumab

Target

VEGFA

Format

scFv

Derivation

Humanized

Species Reactivity

Human

CH1 Isotype

NA

VD LC

Kappa

Highest_Clin_Trial (Jan '20)

Approved

Est. Status

Active

100% SI Structure

None

99% SI Structure

None

95-98% SI Structure

None

Year Proposed

2014

Companies

ESBATech,Alcon

Conditions Approved

Wet age-related macular degeneration

Conditions Active

Diabetic macular oedema,Retinal vein occlusion,Diabetic retinopathy

Conditions Discontinued

NA

Development Tech

NA

Previous Name

NA

Gm Offical Target Name

VEGFA

Package

, ,

Genemeidi Omicron Variant Products
test
Previous slide
Next slide